Yahong Pharmaceuticals (688176.SH): APL-1702 international multicenter Phase III clinical trial results selected for the 2024 International Photodynamic and Photodiagnostic Conference.

YAHONG Pharmaceuticals (688176.SH) announced that their product APL-1702, for the treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) in the cervix, has been selected to present the results of a prospective, randomized, double-blind, placebo-controlled international multicenter Phase III clinical trial at the 2024 International Photodynamic Therapy & Photodiagnosis Update (PDT & PD) conference. The study will be presented in the form of an oral presentation discussing the efficacy data of lowering the pathological grading of precancerous cervical lesions. APL-1702 is a photodynamic therapy product that combines drugs and equipment, used as a non-surgical local treatment for HSIL. The product consists of APL-1702 cream (with 5% HALHCl as the active ingredient) and APL-1702 CL7 device (a vaginal cervical photodynamic therapy cup with LED red light source for treatment).